	US 11,732,047 B2
	FcRn antibodies and methods of use thereof
Marilyn Kehry, San Diego, CA (US); David J. King, Encinitas, CA (US); Leona E. Ling, Winchester, MA (US); James Meador, III, Framingham, MA (US); Sucharita Roy, Tyngsboro, MA (US); and Anthony Manning, Cambridge, MA (US)
Assigned to MOMENTA PHARMACEUTICALS, INC., Titusville, NJ (US)
Filed by Momenta Pharmaceuticals, Inc., Cambridge, MA (US)
Filed on Mar. 20, 2020, as Appl. No. 16/825,066.
Application 16/825,066 is a division of application No. 15/546,870, granted, now 10,676,526, previously published as PCT/US2016/015720, filed on Jan. 29, 2016.
Claims priority of provisional application 62/258,082, filed on Nov. 20, 2015.
Claims priority of provisional application 62/110,071, filed on Jan. 30, 2015.
Prior Publication US 2020/0299382 A1, Sep. 24, 2020
Int. Cl. A61K 39/395 (2006.01); A61K 39/40 (2006.01); C07K 16/28 (2006.01); C07K 16/00 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/283 (2013.01) [A61K 2039/505 (2013.01); C07K 2317/33 (2013.01); C07K 2317/41 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)]

26 Claims

1. A method for treating a disorder selected from the group consisting of pemphigus vulgaris, lupus nephritis, myasthenia gravis, autoimmune haemolytic anaemia (AIHA), chronic inflammatory demyelinating polyneuropathy (CIDP), lupus, systemic lupus, discoid lupus, hemolytic anemia, bullous pemphigoid, polymyositis, dermatomyositis, juvenile arthritis, rheumatic fever, rheumatoid arthritis, and Sjogren's syndrome, the method comprising administering to a patient in need thereof, an isolated antibody that binds to human FcRn, the antibody comprising: (1) a light chain variable region comprising a CDR L1, a CDR L2, and a CDR L3 and (2) a heavy chain variable region comprising a CDR H1, a CDR H2, and a CDR H3, wherein the isolated antibody is selected from the group consisting of:

(a) an antibody wherein CDR L1 comprises the amino acid sequence TGTGSDVGSYNLVS (SEQ ID NO: 1), CDR L2 comprises the amino acid sequence GDSERPS (SEQ ID NO: 2), CDR L3 comprises the amino acid sequence SSYAGSGIYV (SEQ ID NO: 3), CDR H1 comprises the amino acid sequence TYAMG (SEQ ID NO: 4), CDR H2 comprise the amino acid sequence SIGSSGAQTRYADS (SEQ ID NO: 7), and CDR H3 comprises the amino acid sequence LAIGDSY (SEQ ID NO: 11);

(b) an antibody wherein CDR L1 comprises the amino acid sequence TGTGSDVGSYNLVS (SEQ ID NO: 1), CDR L2 comprises the amino acid sequence GDSERPS (SEQ ID NO: 2), CDR L3 comprises the amino acid sequence SSYAGSGIYV (SEQ ID NO: 3), CDR H1 comprises the amino acid sequence DYAMG (SEQ ID NO: 5), CDR H2 comprise the amino acid sequence SIGASGSQTRYADS (SEQ ID NO: 8), and CDR H3 comprises the amino acid sequence LAIGDSY (SEQ ID NO: 11);

(c) an antibody wherein CDR L1 comprises the amino acid sequence TGTGSDVGSYNLVS (SEQ ID NO: 1), CDR L2 comprises the amino acid sequence GDSERPS (SEQ ID NO: 2), CDR L3 comprises the amino acid sequence SSYAGSGIYV (SEQ ID NO: 3), CDR H1 comprises the amino acid sequence NYAMG (SEQ ID NO: 6), CDR H2 comprise the amino acid sequence SIGASGAQTRYADS (SEQ ID NO: 9), and CDR H3 comprises the amino acid sequence LAIGDSY (SEQ ID NO: 11);

(d) an antibody wherein CDR L1 comprises the amino acid sequence TGTGSDVGSYNLVS (SEQ ID NO: 1), CDR L2 comprises the amino acid sequence GDSERPS (SEQ ID NO: 2), CDR L3 comprises the amino acid sequence SSYAGSGIYV (SEQ ID NO: 3), CDR H1 comprises the amino acid sequence TYAMG (SEQ ID NO: 4), CDR H2 comprise the amino acid sequence SIGASGGQTRYADS (SEQ ID NO: 10), and CDR H3 comprises the amino acid sequence LAIGDSY (SEQ ID NO: 11); and

(e) an antibody wherein CDR L1 comprises the amino acid sequence TGTGSDVGSYNLVS (SEQ ID NO: 1), CDR L2 comprises the amino acid sequence GDSERPS (SEQ ID NO: 2), CDR L3 comprises the amino acid sequence SSYAGSGIYV (SEQ ID NO: 3), CDR H1 comprises the amino acid sequence TYAMG (SEQ ID NO: 4), CDR H2 comprise the amino acid sequence SIGASGSQTRYADS (SEQ ID NO: 8) and CDR H3 comprises the amino acid sequence LAIGDSY (SEQ ID NO: 11).